Related MeSH Hierarchy (10)
Diseases [C] » Infections [C01] » Communicable Diseases » Blood-Borne Infections » HIV Infections » HIV-Associated Lipodystrophy Syndrome
Diseases [C] » Infections [C01] » Communicable Diseases » Sexually Transmitted Diseases » Sexually Transmitted Diseases, Viral » HIV Infections » HIV-Associated Lipodystrophy Syndrome
Diseases [C] » Urogenital Diseases [C12] » Genital Diseases » Sexually Transmitted Diseases » Sexually Transmitted Diseases, Viral » HIV Infections » HIV-Associated Lipodystrophy Syndrome
Diseases [C] » Infections [C01] » Sexually Transmitted Diseases » Sexually Transmitted Diseases, Viral » HIV Infections » HIV-Associated Lipodystrophy Syndrome
Diseases [C] » Infections [C01] » Virus Diseases » RNA Virus Infections » Retroviridae Infections » Lentivirus Infections » HIV Infections » HIV-Associated Lipodystrophy Syndrome
Diseases [C] » Infections [C01] » Virus Diseases » Sexually Transmitted Diseases, Viral » HIV Infections » HIV-Associated Lipodystrophy Syndrome
Diseases [C] » Skin and Connective Tissue Diseases [C17] » Skin Diseases » Skin Diseases, Metabolic » Lipodystrophy » HIV-Associated Lipodystrophy Syndrome
Diseases [C] » Nutritional and Metabolic Diseases [C18] » Metabolic Diseases » Lipid Metabolism Disorders » Lipodystrophy » HIV-Associated Lipodystrophy Syndrome
Diseases [C] » Nutritional and Metabolic Diseases [C18] » Metabolic Diseases » Skin Diseases, Metabolic » Lipodystrophy » HIV-Associated Lipodystrophy Syndrome
Diseases [C] » Immune System Diseases [C20] » Immunologic Deficiency Syndromes » HIV Infections » HIV-Associated Lipodystrophy Syndrome
Description
Defective metabolism leading to fat maldistribution in patients infected with HIV. The etiology appears to be multifactorial and probably involves some combination of infection-induced alterations in metabolism, direct effects of antiretroviral therapy, and patient-related factors. MeSH
Hierarchy View
Approved Indicated Drugs (1)
Phase 4 Indicated Drugs (19)
Phase 3 Indicated Drugs (1)
Phase 2 Indicated Drugs (3)
Phase 1 Indicated Drugs (2)
Other Experimental Indicated Drugs (2)
Organization Involved with Phase 4 Indications (16)
Organization Involved with Phase 3 Indications (1)
Organization Involved with Phase 2 Indications (1)
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (1)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
